http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-051802-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| filingDate | 2005-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-051802-A1 |
| titleOfInvention | MCHR1 ANTAGONIST HETEROCICLES |
| abstract | The compounds of formula (1), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, and neurological disorders such as dementia, multiple sclerosis , Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain-related disorders and pharmaceutical compositions that contain them. Claim 1: A compound of formula (1), A represents N, a C1-4 alkyl group, a C2-4 alkenyl group, C3-8 cycloalkyl, adamantyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 1,3- oxazidinyl, tetrahydro-pyridinyl, or spiro [inden-1,4'-piperidinyl]; wherein said C1-4 alkyl group or C2-4 alkenyl group is optionally substituted with one or more fluorine; X represents a link or NR3; where A and X both do not have nitrogen; where when A is azetidinyl, 1,3-oxazidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyridinyl, or spiro [1,4'-piperidinyl]; the nitrogen atom in A is directly linked to C (O); R1 and R2 independently represent H, C1-6 alkyl, a C2-6 alkenyl group, C3-10 cycloalkyl, CONRaRb in which Ra and Rb independently represent H, a C1-4 alkyl group or Ra and Rb, together with the nitrogen to which they are attached, form a 4- to 8-membered heterocyclic ring; phenyl or naphthyl; or a heterocyclic group selected from pyrrolyl, imidazolyl, furyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinolinyl, isoquinolyl, quinazolyl, indolyl, benzofurane, benzofurane, benzofurane, benzofurane, benzofurane, benzofurane benzimidazolyl, benzothiazolyl, 1,4-benzodioxynil, 1,3-benzodioxolyl, piperidinyl, morpholinyl, 1,4-oxazepanyl, or 4,4-dioxothiomorpholinyl; where R1 or R2 is optionally substituted with one or more of the following: cyano; halo; hydroxy; oxo; a C1-4 alkyl group optionally substituted with one or more fluorine; a C1-4 alkoxy group optionally substituted with one or more fluorine; a NCORaRb or CONRaRb group in which Ra and Rb independently represent a C1-3 alkyl group; an SO2C1-4 alkyl group, optionally substituted with one or more fluorine, an aryl or heteroaryl group selected from thiadiazolyl, pyrazolyl, phenyl, phenoxy, 2-pyridyl or 3-pyridyl where said aryl or heteroaryl group may be optionally further substituted with one or more of the following; cyano; halo; hydroxy; a C1-4 alkyl group optionally substituted with one or more fluorine; a C1-4 alkoxy group optionally substituted with one or more fluorine; a NCORaRb or CONRaRb group in which Ra and Rb independently represent a C1-3 alkyl group; a SO2C1-4 alkyl group, optionally substituted with one or more fluorine; R1 and / or R2 is optionally linked to A by means of oxygen or by means of a C1-4 alkyl group, where one of the carbon atoms in said C1-4 alkyl group is optionally replaced with an oxygen atom; Y represents NR3, C (R5R6) or a bond; where at least one of A, X or Y is N, NR3 or a heterocyclic ring containing nitrogen; R3, R5 and R6 independently represent H or a C1-4 alkyl group, D represents (CH2) n, where n is 0 or 1 and E represents (CH2) m, where m is 0 or 1; R4 represents H or, when m and n are both 1, R4 represents H or F; Z represents 2,5-thienyl, 2,5-furyl, or pyrrolyl, optionally substituted with one or more of the following: cyano, halo, a C1-4 alkyl group optionally substituted with one or more fluorine, a C1- alkoxy group 4 optionally substituted with one or more fluorine; W represents phenyl, 2-pyridyl or 3-pyridyl each of which is optionally substituted with one or more of the following: cyano, halo, a C1-4 alkyl group optionally substituted with one or more fluorine, a C1- alkoxy group 4 optionally substituted with one or more fluorine; a trifluoromethylsulfonyl group or a 2,2'-difluoro-oxolanyl group (fused with two adjacent aromatic carbon atoms in W); as well as their tautomers, optical isomers and their racemates as well as their pharmaceutically acceptable salts; with the proviso that when Y represents NR3 then A-X does not represent OCH2, CH2CH2 or CH = CH, where each carbon atom can be optionally substituted with 1 or 2 methyl groups and / or 1 or 2 fluorine. |
| priorityDate | 2004-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.